Clinical Trial

Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.

Study acronym: AKI CAR
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 3, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators want to describe the incidence of AKI after CAR-T cells therapy in B-cell lymphoma. With the aim of highlight risk factors in AKI occurrence. Then, look at outcomes in the subgroup with chronic kidney disease at baseline. Finally, the investigators will examine long term evolution of kidney function.
Trial Details
NCT Number NCT07101913
Lead Sponsor Hospices Civils de Lyon
Conditions Acute Kidney Injury (AKI), Infusion of CD19 CAR T Cell, B Cell Lymphoma
Enrollment 300 participants
Start Date 2025-04-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-03